The intestinal microbiota dysbiosis and Clostridium difficile infection: Is there a relationship with inflammatory bowel disease?

Therapeutic Advances in Gastroenterology

Volumn 6, Issue 1, 2013, Pages 53-68

  Bien, Justyna ^a   Palagani, Vindhya ^b   Bozko, Przemyslaw ^b  

^a W STEFA SKI INSTITUTE OF PARASITOLOGY   (Poland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clostridium difficile; Inflammatory bowel disease; Microbial dysbiosis

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENTERITIS; HUMAN; INTESTINE FLORA; MICROBIAL DYSBIOSIS; NONHUMAN; ORGANISMAL INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84871661864     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12454590     Document Type: Review

References (132)

1. Agans R. Rigsbee L. Kenche H. Michail S. Khamis H. Paliy O. (2011) Distal gut microbiota of adolescent children is different from that of adults. FEMS Microbiol Ecol 77: 404–412.
2. Aldeyab M. Harbarth S. Vernaz N. et al. (2009) Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 53: 2082–2088.
3. Ananthakrishnan A. McGinley E. Binion D. (2008) Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57: 205–210.
4. Bäckhed F. Ley R. Sonnenburg J. Peterson D. Gordon J. (2005) Host–bacterial mutualism in the human intestine. Science 307: 1915–1920.
5. Barc M. Bourlioux F. Janoir C. Rigothier-Gois L. Boureau H. Doré J. et al. (2004) Effect of amoxicillin clavulanate on human fecal flora in a gnotobiotic mouse model measured with group specific 16S r RNA targeted oligonucleotide probes in combination with flow cytometry. Antimicrob Agents Chemother 48: 1365–1368.
6. Barnes P. (1997) Nuclear factor-κB. Int J Biochem 29: 867.
7. Beltman J. Erickson J. Martin G. Lyons J. Cook S. (1999) C3 toxin activates the stress signaling pathways, JNK and p 38, but antagonizes the activation of AP-1 in rat-1 cells. J Biol Chem 274: 3772–3780.
8. Bernstein C. Shanahan F. (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57: 1185–1191.
9. Bolton R. Read A. (1982) Clostridium difficile in toxic megacolon complicating acute inflammatory bowel disease. Br Med J (Clin Res Ed) 285: 475–476.
10. Bolton R. Tait S. Dear P. (1984) Asymptomatic neonatal colonization by Clostridium difficile. Arch Dis Child 59: 466–472.
11. Bossuyt P. Verhaegen J. van Assche G. Rutgeerts P. Vermeire S. (2009) Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis 3: 4–7.
12. Brito G. Fujji J. Carneiro-Filho B. Lima A. Obrig T. Guerrant R. (2002) Mechanism of Clostridium difficile toxin A-induced apoptosis in T 84 cells. J Infect Dis 186: 1438–1447.
13. Bry L. Falk P. Midtvedt T. Gordon J. (1996) A model of host microbial interactions in an open mammalian ecosystem. Science 273: 1380–1383.
14. Burnham W. Lennard-Jones J. Stanford J. Bird R. (1978) Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 2: 693–696.
15. Brüggemann H. Gottschalk G. (2008) Comparative genomics of clostridia link between the ecological niche and cell surface properties. Ann N Y Acad Sci 1125: 73–81.
16. Cash H. Whitham C. Behrendt C. Hooper L. (2006) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313: 1126–1130.
17. Chang J. Antonopoulos D. Kalra A. Tonelli A. Khalife W. Schmidt T. et al. (2008) Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197: 435–438.
18. Collignon A. Ticchi L. Depitre C. Gaudelus J. Delmée M. Corthier G. et al. (1993) Heterogeneity of Clostridium difficile isolates from infants. Eur J Pediatr 152: 319–322.
19. Collins M. Lawson P. Willems A. Cordoba J. Fernandez-Garayzabal J. Garcia P. et al. (1994) The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 44: 812–826.
20. Danese S. Fiocchi C. (2006) Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 12: 4807–4812.
21. Darfeuille-Michaud A. Boudeau J. Bulois P. Neut C. Glasser A. Barnich N. et al. (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412–421.
22. Daub H. Weiss F. Wallasch C. Ullrich A. (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557–560.
23. de La Cochetière M. Durand T. Lalande V. Petit J. Potel G. Beaugerie L. 2008. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 56:395–402.
24. Dial S. Delaney J. Barkun A. Suissa S. (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989–2995.
25. Dial S. Delaney J. Schneider V. Suissa S. (2006) Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175: 745–748.
26. Dobson G. Hickey C. Trinder J. (2003) Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med 29: 1030.
27. Eckburg P. Bik E. Bernstein C. Purdom E. Dethlefsen L. Sargent M. et al. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635–1638.
28. Falony G. Vlachou A. Verbrugghe K. de Vuyst L. (2006) Crossfeeding between Bifidobacterium longum BB 536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl Environ Microbiol 72: 7835–7841.
29. Farrell R. La Mont J. (2002) Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 31: 41–62.
30. Fiorentini C. Fabbri A. Falzano L. Fattorossi A. Matarrese P. Rivabene R. et al. (1998) Clostridium difficile toxin B induces apoptosis in intestinal cultured cells. Infect Immun 66: 2660–2665.
31. Flegel W. Müller F. Daubener W. Fischer H. Hadding U. Northoff H. (1991) Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infec Immun 59: 3659.
32. Frank D. St Amand A. Feldman R. Boedeker E. Harpaz N. Pace N. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: 13780–13785.
33. Freeman H. (2008) Recent developments on the role of Clostridium difficile in inflammatory bowel disease. World J Gastroenterol 14: 2794–2796.
34. García Rodríguez L. Ruigómez A. Panés J. (2006) Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130: 1588–1594.
35. George R. (1986) The carrier state: Clostridium difficile. Antimicrob Chemother 18(Suppl. A): 47–58.
36. Gerding D. Johnson B. Peterson L. Mulligan M. Silva J. Jr. (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16: 459.
37. Hawrelak J. Myers S. (2004) The causes of intestinal dysbiosis: a review. Altern Med Rev 9: 180–197.
38. Hecht G. Koutsouris A. Pothoulakis C. La Mont J. Madara J. (1992) Clostridium difficile toxin B disrupts the barrier function of T 84 monolayers. Gastroenterology 102: 416–423.
39. Hennequin C. Janoir C. Barc M. Collignon A. Karjalainen T. (2003) Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 149: 2779–2787.
40. Hennequin C. Porcheray F. Waligora-Dupriet A. Collignon A. Barc M. Bourlioux P. et al. (2001) Gro EL (Hsp60) of Clostridium difficile is involved in cell adherence. Microbiology 147: 87–96.
41. Henriques B. Florin I. Thelestam M. (1987) Cellular internalisation of Clostridium difficile toxin A. Microb Pathog 2: 455–463.
42. Hopkins M. Macfarlane G. Furrie E. Fite A. Macfarlane S. (2005) Characterisation of intestinal bacteria in infant stools using real-time PCR and northern hybridisation analyses. FEMS Microbiol Ecol 54: 77–85.
43. Hold G. Pryde S. Russell V. Furrie E. Flint H. (2002) Assessment of microbial diversity in human colonic samples by 16S r DNA sequence analysis. FEMS Microbiol Ecol 39: 33–39.
44. Holzapfel W. Haberer P. Snel J. Schillinger U. Huis in't Veld J. (1998) Overview of gut flora and probiotics. Int J Food Microbiol 41: 85–101.
45. Hooper L. Midwedt T. Gordon J. (2002) How host microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 22: 283–307.
46. Iizuka M. Itou H. Konno S. Chihara J. Tobita M. Oyamada H. et al. (2004) Elemental diet modulates the growth of Clostridium difficile in the gut flora. Aliment Pharmacol Ther 20: 151–157.
47. Issa M. Vijayapal A. Graham M. Beaulieu D. Otterson M. Lundeen S. et al. (2007) Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepat 5: 345–351.
48. Jacobs N. Jr. (1994) Antibiotic-induced diarrhea and pseudomembranous colitis. Postgrad Med 95: 111–120.
49. Jank T. Giesemann T. Aktories K. (2007) Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17: 15–22.
50. Jarvis W. Schlosser J. Jarvis A. Chinn R. (2009) National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 37: 263–270.
51. Jefferson K. Smith M. Bobak D. Jr (1999) Roles of intracellular calcium and NF-κB in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 163: 5183–5191.
52. Jernberg C. Lofmark S. Edlund C. Jansson J. (2007) Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 1: 56–66.
53. Just I. Selzer J. Wilm M. von Eichel-Streiber C. Mann M. Aktories K. (1995) Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375: 500–503.
54. Keighley M. Youngs D. Johnson M. Allan R. Burdon D. (1982) Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut 23: 410–414.
55. Kelly C. La Mont J. (1998) Clostridium difficile infection. Annu Rev Med 49: 375–390.
56. Kim J. Lee J. Yoon Y. Ohz Y. Youny J. Kim Y. (2006) NF-κB activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scan J Immunol 63: 453–546.
57. Kim H. Rhee S. Kokkotou E. Na X. Savidge T. Moyer M. et al. (2005) Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E 2 synthesis in colonocytes via reactive oxygen species and activation of p 38 MAPK. J Biol Chem 280: 21237–21245.
58. Kobayashi T. (1983) Studies on Clostridium difficile and antimicrobial associated diarrhea or colitis. Jpn J Antibiot 36: 464–476.
59. Koike T. Kuzuya M. Asai T. Kanda S. Cheng X. Watanabe K. et al. (2000) Activation of MMP-2 by Clostridium difficile toxin B in bovine smooth muscle cells. Biochem Biophys Res Commun 277: 43–46.
60. Krivan H. Clark G. Smith D. Wilkins T. (1986) Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1–3Gal beta 1–4GlcNAc. Infect Immun 53: 573–581.
61. Kuijper E. Coignard B. Tull P. (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12: 2–18.
62. La Mont J. Trnka Y. (1980) Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1: 381–383.
63. Lepage P. Colombet J. Marteau P. Sime-Ngando T. Dore J. Leclerc M. (2008) Dysbiosis in inflammatory bowel disease: a role for bacteriophages? Gut 57: 424–425.
64. Ley R. Hamady M. Lozupone C. Turnbaugh P. Ramey R. Bircher J. et al. (2008) Evolution of mammals and their gut microbes. Science 320: 1647–1651.
65. Ley R. Peterson D. Gordon J. (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837–848.
66. Lidar M. Langevitz P. Shoenfeld Y. (2009) The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. IMAJ 11: 558–563.
67. Linevsky J. Pothoulakis C. Keates S. Warny M. Keates A. Lamont J. et al. (1997) IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 273: 1333–1340.
68. Lyras D. O'Connor J. Howarth P. Sambol S. Carter G. Phumoonna T. et al. (2009) Toxin B is essential for virulence of Clostridium difficile. Nature 458: 1176–1179.
69. Mahida Y. Makh S. Hyde S. Gray T. Borriello S. (1996) Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 38: 337–347.
70. Manges A. Labbe A. Loo V. Atherton J. Behr M. Masson L. et al. (2010) Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 202: 1877–1884.
71. Manichanh C. Rigottier-Gois L. Bonnaud E. Gloux K. Pelletier E. Frangeul L. et al. (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205–211.
72. Marchesi J. Shanahan F. (2007) The normal intestinal microbiota. Curr Opin Infect Dis 20: 508–513.
73. Marcille F. Gomez A. Joubert P. Ladiré M. Veau G. Clara A. et al. (2002) Distribution of genes encoding the trypsin-dependent antibiotic ruminococcin A among bacteria isolated from human fecal microbiota. Appl Environ Microbiol 68: 3424–3431.
74. Mazmanian S. Liu C. Tzianabos A. Kasper D. (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122: 107–118.
75. McFarland L. (1998) Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 16: 292–307.
76. McFarland L. Beneda H. Clarridge J. Raugi G. (2007) Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35: 237–253.
77. Meyers S. Mayer L. Bottone E. Desmond E. Janowitz H. (1981) Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 80: 697–770.
78. Montaner S. Perona R. Saniger L. Lacal J. (1998) Multiple signalling pathways lead to the activation of the nuclear factor κB by the Rho family of GT Pases. J Biol Chem 273: 12779–12785.
79. Moore R. Pothoulakis C. La Mont J. Carlson S. Madara J. (1990) C. difficile toxin A increases intestinal permeability and induces Cl– secretion. Am J Physiol 259: G165–G172.
80. Musa S. Thomson S. Cowan M. Rahman T. (2010) Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol 45: 261–272.
81. Mylonakis E. Ryan E. Calderwood S. (2001) Clostridium difficile-associated diarrhea. Arch Intern Med 161: 525–533.
82. Na X. Zhao D. Koon H. Kim H. Husmark J. Moyer M. et al. (2005) Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 128: 1002–1011.
83. Nakamura S. Mikawa M. Nakashio S. Takabatake M. Okado I. Yamakawa K. et al. (1981) Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 25: 345–351.
84. Naumann M. Rudel T. Wieland B. Bartsch C. Meyer T. (1998) Coordinate activation of activator protein 1 and inflammatory cytokines in response to neisseria gonorrhoeae epithelial cell contact involves stress response kinases. J Exp Med 188: 1277–1286.
85. Nerandzic M. Pultz M. Donskey C. (2009) Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 53: 4133–4137.
86. Nomura K. Fujimoto Y. Yamashita M. Morimoto Y. Ohshiro M. Sato K. et al. (2009) Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 44: 74–78.
87. O'Keefe S. (2008) Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol 24: 51–58.
88. O'Keefe S. (2010) Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 16: 139–142.
89. Palmer C. Bik E. Di Giulio D. Relman D. Brown P. (2007) Development of the human infant intestinal microbiota. PLoS Biol 5: e177.
90. Pan Z. Ye R. Christiansen S. Jagels M. Bokoch G. Zuraw B. (1998) Role of Rho GT Pase in bradykinin-stimulated nuclear factor-kB activation and IL-1β gene expression in cultured human epithelial cells. J Immunol 160: 3038–3045.
91. Pechine S. Janoir C. Boureau H. Gleizes A. Tsapis N. Hoys S. et al. (2007) Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25: 3946–3954.
92. Pepin J. Valiquette L. Alary M. Villemure P. Pelletier A. Forget K. et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472.
93. Perona R. Montaner S. Saniger L. Sanchez-Perez I. Bravo R. Lacal J. (1997) Activation of the nuclear factor-κB by Rho, CDC 42 and Rac-1 proteins. Genes Dev 11: 463–475.
94. Peterson D. Frank D. Pace N. Gordon J. (2008) Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3: 417–427.
95. Pothoulakis C. La Mont J. (2001) Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 280: 178–183.
96. Powell N. Jung S. Krishnan B. (2008) Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut 57: 1183–1184.
97. Pryde S. Duncan S. Hold G. Stewart C. Flint H. (2002) The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217: 133–139.
98. Rajilić-Stojanović M. Smidt H. de Vos W. (2007) Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 9: 2125–2136.
99. Rodemann J. Dubberke E. Reske K. da Seo H. Stone C. (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 339–344.
100. Rolfe R. Helebian S. Finegold S. (1981) Bacterial interference between Clostridium difficile and normal fecal flora. J Infect Dis 143: 470–475.
101. Rousseau C. Levenez F. Fouqueray C. Dore J. Collignon A. Lepage P. (2011) Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol 49: 858–865.
102. Savage D. (1977) Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31: 107–133.
103. Savidge T. Pan W. Newman P. O'Brien M. Anton P. Pothoulakis C. (2003) Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125: 413–420.
104. Schirmer J. Aktories K. (2004) Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim Biophys Acta 1673: 66–74.
105. Schumacher G. Kollberg B. Sandstedt B. Jorup C. Grillner L. Ljungh A. et al. (1993) A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Scand J Gastroenterol 28: 1077–1085.
106. Segain J. de la Raingeard B. Bourreille A. Leray V. Gervois N. Rosales C. et al. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47: 397–403.
107. Skaros S. Weber L. Komorowski R. Knox J. Emmons J. Bajaj J. et al. (2007) Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 345–351.
108. Sokol H. Seksik P. Furet J. Firmesse O. Nion Larmurier I. Beauqerie G. et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183–1189.
109. Springer T. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301–314.
110. Stallmach A. Carstens O. (2002) Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis 8: 213–218.
111. Starr J. (2005) Clostridium difficile associated diarrhoea: diagnosis and treatment. BMJ 331: 498–501
112. Sullivan A. Edlund C. Nord C. (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1: 101–114.
113. Suzuki A. Sekiya S. Gunshima E. Fujii S. Taniguchi H. (2010) EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture. Lab Invest 90:1425–1436
114. Swidsinski S. Ladhoff A. Pernthaler A. Swidsinski S. Loening-Baucke V. Ortner M. et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44–54.
115. Tamboli C. Neut C. Desreumaux P. Colombel J. (2004) Dysbiosis in inflammatory bowel disease. Gut 53: 1–4.
116. Tasteyre A. Barc M. Collignon A. Boureau H. Karjalainen T. (2001) Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 69: 7937–7940.
117. Taylor R. Borriello S. Taylor A. (1981) Isolation of Clostridium difficile from the small bowel. Br Med J (Clin Res Ed) 283: 412.
118. Testore G. Nardi F. Babudieri S. Giuliano M. Di Rosa R. Panichi G. (1986) Isolation of Clostridium difficile from human jejunum: identification of a reservoir for disease? J Clin Pathol 39: 861–862.
119. Thomson A. Sauve M. Kassam N. Kamitakahara H. (2010) Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 16: 2323–2330.
120. Trnka Y. La Mont J. (1981) Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 80: 693–696.
121. Tsironi E. Irving P. Feakins R. Rampton D. (2006) ‘Diversion’ colitis caused by Clostridium difficile infection: report of a case. Dis Colon Rectum 49: 1074–1077.
122. Tullus K. Aronsson B. Marcus S. Mollby R. (1989) Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 8: 390–393.
123. Tvade M. Rask-Madsen J. (1989) Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1: 1156–1160.
124. Voth D. Ballard J. (2005) Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18: 247–263.
125. Waligora A. Hennequin C. Mullany P. Bourlioux P. Collignon A. Karjalainen T. (2001) Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 69: 2144–2153.
126. Wang M. Ahrne S. Jeppsson B. Molin G. (2005) Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S r RNA genes. FEMS Microbiol Ecol 54: 219–231.
127. Warny M. Keates A. Keates S. Castagliuolo I. Zacks J. Aboudola S. et al. (2000) p 38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 105: 1147–1156.
128. Wesselborg S. Bauer M. Vogt M. Schmitz M. Schulze-Osthoff K. (1998) Activation of transcription factor NF-kB and p 38 mitogen-activated protein kinase is mediated by distinct and separate stress effector pathways. J Biol Chem 272: 12422–12429.
129. Wilson K. (1993) The microecology of Clostridium difficile. Clin Infect Dis 16: 214–218.
130. Wultańska D. Banaszkiewicz A. Radzikowski A. Obuch-Woszczatyński P. Młynarczyk G. Brazier J. et al. (2010) Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis 29: 1265–1270.
131. Zoetendal E. Akkermans A. de Vos W. (1998) Temperature gradient gel electrophoresis analysis of 16S r RNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64: 3854–3859.
132. Zoetendal E. Rajilic-Stojanovic M. de Vos W. (2008) High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57: 1605–1615.